Article

Nidek's hyperopia algorithm tops FDA criteria

Fremont, CA-The FDA has given the go-ahead to an expansion of Nidek Inc.'s hyperopia study using new software for its U.S. EC-5000 platform.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
(Image credit: AdobeStock/sky_diez) EyeCon 2025: A collaborative vision for the future of eye care
September 17th 2025

EyeCon 2025: Sun, sea, and a shared vision for the future of eye care

3 Things You Should Know About the GA Pipeline
September 17th 2025

NK Insights: An Interactive Corneal Sensitivity Testing Workshop

Kodiak announces new data from APEX study of KSI-101
September 17th 2025

Kodiak announces new data from APEX study of KSI-101

3 Things You Should Know About the GA Pipeline
September 17th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Time and motion studies demonstrate workflow efficiencies of Alcon’s Unity VCS in cataract and vitreoretinal surgery
September 17th 2025

Time and motion studies demonstrate workflow efficiencies of Alcon’s Unity VCS in cataract and vitreoretinal surgery

Sagent Pharmaceuticals enters ophthalmic market, launches travoprost ophthalmic solution, USP 0.004%
September 17th 2025

Sagent Pharmaceuticals enters ophthalmic market, launches travoprost ophthalmic solution, USP 0.004%

© 2025 MJH Life Sciences

All rights reserved.